Fig. 6

In vivo combined antitumor effects of Exo-Lut-NPs and sorafenib on a HepG2/LX2 subcutaneous xenograft tumor model. A Schematic illustration of the establishment of HCC subcutaneous xenograft mouse model of HepG2 cells and LX2 cells, and the following treatment schedule. Created with https://www.biorender.com/. B Body weight of tumor-bearing mice before treatment. C Tumor growth trend of the tumor-bearing mice in the control group. D Tumor growth trend after different treatments, which were (i) normal saline (control group), (ii) sorafenib (50 mg/kg), (iii) sorafenib (50 mg/kg) combined with Lut-NPs (equivalent luteolin dose of 0.48 mg/kg), and (iv) sorafenib (50 mg/kg) combined with Exo-Lut-NPs (equivalent luteolin dose of 0.48 mg/kg) for a 12-day treatment. E Body weight of tumor-bearing mice after different treatment. Data are represented as mean ± SD (n = 5), *P < 0.05, **P < 0.01, ***P < 0.001